Pulse Biosciences, Inc. (PLSE)

Over the past six months, Pulse Biosciences' stock has experienced notable movements influenced by clinical advancements and financial reporting, with returns of 7.0% over 7 days, 28.1% over 30 days, 71.8% year to date, and 58.3% over one year as of April 3, 2026. Key events impacting the stock price include financial results conference calls, presentations at healthcare conferences, acceleration of the cardiac catheter program, strengthening of the executive leadership team with the appointment of Liane Teplitsky as Chief Operating Officer, and enrollment in the NANOPULSE-AF IDE pivotal clinical study. The stock price on April 6, 2026, was $22.94 per share, representing a 51.32% increase from April 7, 2025, but decreased by -3.01% on April 10, 2026, dropping to $18.67, and had declined by -13.16% over the preceding 10 days.

The provided information does not indicate specific demand seasonality for Pulse Biosciences' products and services; however, the broader markets in which Pulse Biosciences operates, such as ablation devices for cardiology and dermatology, exhibit general trends, with the global ablation devices market experiencing strong and sustained growth driven by the rising prevalence of chronic diseases and increasing technological advancements.

Pulse Biosciences, Inc. is a bioelectric medicine company focused on developing and commercializing medical devices based on its proprietary Nano-Pulse Stimulation (NPS) technology, also known as Nanosecond Pulsed-Field Ablation (nsPFA) technology, which delivers ultrashort, high-voltage electric pulses to targeted tissue. The company's major products and platforms include the CellFX® System / nPulse System for treating benign skin lesions, the CellFX nsPFA Percutaneous Electrode System / nPulse Vybrance Percutaneous Electrode system for soft tissue ablation, the CellFX nsPFA Cardiac Clamp / nPulse Cardiac Surgical Clamp for atrial fibrillation treatment, the CellFX nsPFA 360° Cardiac Catheter / nPulse Cardiac Catheter System for circumferential ablation in atrial fibrillation, and the CellFX Console / nPulse Console, a tunable, software-enabled platform.

Pulse Biosciences, Inc. is headquartered in Miami, Florida, with a corporate office also mentioned in Hayward, California. The company operates in North America and Europe, collaborating with key opinion leaders in dermatology and medical research institutions.

Information explicitly detailing Pulse Biosciences' brand reputation is not readily available; however, the company's reputation is likely influenced by its ongoing clinical trial advancements, such as the successful procedural outcomes for its nPulse Cardiac Catheter System and the enrollment of patients in pivotal studies for atrial fibrillation and benign thyroid nodules, as well as executive team changes.

Pulse Biosciences, Inc. has a mixed ownership structure, with approximately 73.34% of the company's stock owned by insiders, institutional investors holding around 1.48% to 9.30%, and retail investors holding about 9.33% to 20.13%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Bank of America Corporation. The largest individual shareholder is Robert W. Duggan, who owns 49.39 million shares, representing 72.65% of the company.